Arbutus biopharma corp (ABUS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenue
Collaborations and contracts

-

-

-

229

11,712

11,738

10,425

12,105

16,311

-

Licensing fees, milestone and royalty payments

-

-

-

1,262

11,564

3,215

5,040

2,000

500

-

Revenue

6,011

5,945

10,700

1,491

23,276

14,953

15,465

14,105

16,811

-

Non-cash royalty revenue

1,656

0

-

-

-

-

-

-

-

-

Operating expenses
Non-cash royalty revenue
Research and development

57,601

57,934

62,676

61,253

51,505

38,713

21,458

18,043

20,131

-

General and administrative

17,727

16,002

16,129

39,438

26,438

8,683

5,546

8,141

6,386

-

Depreciation

2,028

2,181

2,027

1,092

589

529

613

866

986

-

Gain on disposition of financial instrument

-

-

-

1,000

0

0

-

-

-

-

Warrant issuance costs (note 5)

-

-

-

-

-

-

-

47

80

-

Fair Value, Option, Changes in Fair Value, Gain (Loss)

-

-

-22

530

3,341

-10,383

-3,530

-3,822

579

-

Change in fair value of contingent consideration

-173

-7,298

1,359

1,568

770

0

0

-

-

-

Site consolidation

156

4,797

0

-

-

-

-

-

-

-

Acquisition costs

-

-

-

0

9,656

462

0

-

-

-

Impairment of Intangible Assets (Excluding Goodwill)

43,836

14,811

40,798

253,197

39,007

0

0

-

-

-

Impairment of goodwill

22,471

0

-

138,150

0

0

-

-

-

-

Licensing settlement payment (note 3(c))

-

-

-

-

-

-

-

65,000

-

-

Legal Fees

6,266

0

-

-

-

-

-

18,738

-

-

Total operating expenses

150,085

95,725

121,630

493,130

127,195

48,387

27,617

27,050

27,505

-

Total operating expenses

-144,074

-89,780

-110,930

-491,639

-103,919

-33,434

-12,152

-12,945

-10,693

-

Loss from operations
Interest income

2,111

3,047

1,538

1,391

674

853

540

138

126

-

Interest expense

2,108

226

261

0

0

-

-

-

-

-

Foreign exchange (losses) / gains

41

-1,003

2,301

1,120

21,771

4,127

1,079

25

-14

-

Other income - Net equity investment gain or loss

-22,522

19,322

-

-

-

-

-

-

-

-

Gain (Loss) on Investments

-

-

0

-

-

-

-

-

-

-

Net equity investment loss

-

-

0

-

-

-

-

-

-

-

Total other loss

-22,305

28,438

2,197

2,473

25,016

-5,403

-1,911

-

-

-

Loss before income taxes

-166,379

-61,342

-

-

-

-

-

-

-

-

Loss before income taxes

-

-

-108,733

-489,166

-78,903

-38,837

-14,063

-

-

-

Income tax benefit

-12,656

-4,282

-24,320

-105,002

-16,185

0

0

-

-

-

Net Income (Loss) Attributable to Parent

-153,723

-57,060

-84,413

-384,164

-62,718

-38,837

-14,063

29,611

-10,083

-

Items applicable to preferred shares:
Dividend accretion of convertible preferred shares

11,149

10,091

911

0

0

-

-

-

-

-

Net loss attributable to common shares

-164,872

-67,151

-85,324

-384,164

-62,718

-

-

-

-

-

Net loss attributable to common shareholders, per share
Basic (in USD per share)

-

-

-1.56

-7.24

-1.38

-1.80

-0.92

2.16

-0.89

-

Diluted (in USD per share)

-

-

-1.56

-7.24

-1.38

-1.80

-0.92

2.07

-0.89

-

Basic and dilutive (in USD per share)

-2.89

-1.21

-

-

-

-

-

-

-

-

Net loss per common share
Weighted average number of common shares
Basic (in shares)

-

-

54,723

53,074

45,462

21,603

15,302

13,727

11,318

10,332

Weighted Average Number of Shares Outstanding, Diluted

-

-

54,723

53,074

45,462

21,603

15,302

14,320

11,318

10,332

Comprehensive income
Currency translation adjustment

-59

15

0

0

-25,872

-6,489

-3,135

474

-53

-

Comprehensive loss

-153,782

-57,045

-84,413

-384,164

-88,590

-45,326

-17,198

30,085

-10,136

-

Collaboration And Contracts [Member]
Revenue

4,355

5,945

-

-

-

-

-

-

-

-

Royalty [Member]
Non Cash Royalty Revenue Related To Sale Of Future Royalties

-1,656

-

-

-

-

-

-

-

-

-

Common Shares
Preferred Stock Dividends and Other Adjustments

0

0

-

-

-

-

-

-

-

-

Net loss attributable to common shares

-164,872

-67,151

-

-

-

-

-

-

-

-

Earnings Per Share, Basic and Diluted

-2.89

-1.21

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Basic and Diluted

57,093

55,304

-

-

-

-

-

-

-

-